Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -0.29% is 100% above its 4-year average of -174.11%, near the high end of its 4-year range (-1589.08%–16.56%).
99.78% above its 12-month average of -129.00%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2026 (2026-06-30): -0.14%.
EBITDA MARGIN
-0.29%
EBITDA MARGIN AVG TTM
-129.00%
EBITDA MARGIN AVG 3Y
-144.79%
EBITDA MARGIN AVG 5Y
-174.11%
EBITDA MARGIN AVG 10Y
-174.11%
EBITDA MARGIN AVG 15Y
-229.10%
EBITDA MARGIN AVG 20Y
-195.38%
CURRENT VS TTM AVG
+99.78%
CURRENT VS 3Y AVG
+99.80%
CURRENT VS 5Y AVG
+99.83%
CURRENT VS 10Y AVG
+99.83%
CURRENT VS 15Y AVG
+99.87%
CURRENT VS 20Y AVG
+99.85%
InMed Pharmaceuticals Inc.
Market Cap
$7.31M
EBITDA Margin
-0.29%
TTM Avg
-129.00%
3Y Avg
-144.79%
5Y Avg
-174.11%
Market Cap
$7.25M
EBITDA Margin
1.07%
TTM Avg
13.21%
3Y Avg
13.21%
5Y Avg
13.21%
Market Cap
$7.50M
EBITDA Margin
-3822.36%
TTM Avg
-2499.82%
3Y Avg
-7123.25%
5Y Avg
-7123.25%
Market Cap
$7.18M
EBITDA Margin
-1839.87%
TTM Avg
-1245.27%
3Y Avg
-1681.64%
5Y Avg
-1341.06%
Market Cap
$7.07M
EBITDA Margin
3.56%
TTM Avg
3.56%
3Y Avg
3.56%
5Y Avg
3.56%
Market Cap
$7.00M
EBITDA Margin
-2068.24%
TTM Avg
-1510.83%
3Y Avg
-1474.78%
5Y Avg
-1474.78%
Market Cap
$6.97M
EBITDA Margin
-4847.72%
TTM Avg
-2918.14%
3Y Avg
-1630.06%
5Y Avg
-1069.46%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $7.31M | -0.29% | -129.00% | -144.79% | -174.11% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.25M | 1.07% | 13.21% | 13.21% | 13.21% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.50M | -3822.36% | -2499.82% | -7123.25% | -7123.25% |
| Longeveron Inc. (LGVN)vs › | $7.18M | -1839.87% | -1245.27% | -1681.64% | -1341.06% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | 3.56% | 3.56% | 3.56% | 3.56% |
| KALA BIO, Inc. (KALA)vs › | $7.00M | -2068.24% | -1510.83% | -1474.78% | -1474.78% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.56M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.95M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.97M | -4847.72% | -2918.14% | -1630.06% | -1069.46% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.76M | -144973.96% | -73136.05% | -36678.29% | -29395.87% |
Gross Margin
14.9%
EBITDA Margin
-0.3%
Operating Margin
-0.5%
Net Margin
-0.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -0.14% |
| 2025-12-31 | -239.30% |
| 2025-09-30 | -143.47% |
| 2025-06-30 | -133.10% |
| 2025-03-31 | -157.40% |
| 2024-12-31 | -186.85% |
| 2024-09-30 | -127.25% |
| 2024-06-30 | -144.74% |
| 2024-03-31 | -140.33% |
| 2023-12-31 | -125.16% |
| 2023-09-30 | 16.56% |
| 2023-06-30 | -17.71% |
| 2023-03-31 | -194.07% |
| 2022-12-31 | -454.68% |
| 2022-09-30 | -1054.00% |
| 2022-06-30 | -563.93% |
| 2022-03-31 | -1097.22% |
| 2021-12-31 | -1589.08% |
| 2011-06-30 | -1286.30% |
| 2011-03-31 | -942.04% |
| 2010-12-31 | -138.97% |
| 2010-09-30 | -310.05% |
| 2010-06-30 | -173.92% |
| 2010-03-31 | -1353.59% |
| 2009-12-31 | -2894.76% |
| 2009-09-30 | -429.12% |
| 2009-06-30 | -273.87% |
| 2008-09-30 | -195.19% |
| 2008-06-30 | 120.22% |
| 2008-03-31 | -47.29% |
| 2007-12-31 | -67.15% |
| 2007-09-30 | -357.63% |
| 2007-06-30 | 1481.04% |
| 2006-12-31 | -2527.11% |
| 2006-09-30 | -40.47% |
| 2006-06-30 | -3.67% |
| 2006-03-31 | -65.44% |
| 2005-12-31 | -27.44% |
| 2005-09-30 | -38.39% |
| 2005-06-30 | -31.34% |
| 2005-03-31 | -11.87% |
| 2004-12-31 | -19.04% |
| 2004-09-30 | -134.23% |
| 2004-07-31 | -88.95% |
| 2004-04-30 | -32.86% |
| 2004-01-31 | -48.50% |
| 2003-10-31 | -21.48% |
| 2003-07-31 | -228.14% |
| 2003-04-30 | -963.58% |
| 2003-01-31 | -30690.34% |
| 2002-10-31 | -2104.78% |
